Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Takayuki IwamotoNaoki NiikuraKenichi WatanabeTakashi TakeshitaYuichiro KikawaKokoro KobayashiNobutaka IwakumaTakuho OkamuraHiroshi TadaShinji OzakiToshitaka OkunoUhi TohYutaka YamamotoMichiko TsuneizumiHiroshi IshiguroNorikazu MasudaShigehira SajiPublished in: Breast cancer research and treatment (2023)
No significant association was observed between changes in mutated genes after short-term palbociclib and fulvestrant treatment and disease progression; a significant reduction in cfDNA mutation level was observed on day 15 of cycle one. Clinical meanings of cfDNA should be investigated in the future trials.